Sanofi SA (LTS:0A2V)
$ 49 0 (0%) Market Cap: 122.85 Bil Enterprise Value: 141.18 Bil PE Ratio: 28.19 PB Ratio: 1.63 GF Score: 87/100

Sanofi SA at Citi BioPharma Conference Transcript

Sep 06, 2023 / 05:50PM GMT
Release Date Price: $52.61 (-0.73%)
Peter Verdult
Citigroup Inc., Research Division - MD

(technical difficulty) today. Now some of you will have an older version of the itinerary and realize that I don't have Bill Sibold sitting next to me. But rather than just canceling on us after Bill's departure last week, (inaudible) stepped up and have given us 2 speakers, really topical. Brian Foard, who did run Dupixent and some of you met him at the immunology session last year. He's now the Head of Specialty Care North America and Country Head for the U.S. and Kim Tutwiler, Head of RSV Development. So very timely to have both of you here, and thank you very much for just pulling out and coming.

So I'll try and make this as interactive as possible. Those that know me will know I always say this here to moderate, not monopolize. If any of you want to ask questions, shout out, stick your hand up or actually have been told in the back, wait for the mic before you ask your questions. But before we do that, I think Brian wants to make some opening remarks, and then we'll go into some Q&A. So Brian, Kim, thank you. Over to you.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot